IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$483.73 USD
-2.27 (-0.47%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $483.50 -0.23 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Idexx Laboratories (IDXX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$578.67 | $650.00 | $500.00 | 19.63% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Idexx Laboratories comes to $578.67. The forecasts range from a low of $500.00 to a high of $650.00. The average price target represents an increase of 19.63% from the last closing price of $483.73.
Analyst Price Targets (9 )
Broker Rating
Idexx Laboratories currently has an average brokerage recommendation (ABR) of 1.77 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.77 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, six are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 54.55% and 9.09% of all recommendations. A month ago, Strong Buy made up 54.55%, while Buy represented 9.09%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/IDXX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/5/2024 | Piper Sandler | David M Westenberg | Hold | Hold |
5/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/2/2024 | Atlantic Equities | Steven K Chesney | Hold | Hold |
5/1/2024 | Not Identified | Not Identified | Hold | Hold |
4/9/2024 | William Blair | Ryan S Daniels | Strong Buy | Strong Buy |
1/17/2024 | Goldman Sachs | Nathan Rich | Strong Buy | Strong Buy |
12/7/2023 | Exane BNP Paribas | Navann Ty | Not Available | Strong Buy |
12/4/2023 | Cleveland Research Company | Robert Eich | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.77 |
ABR (Last week) | 1.77 |
# of Recs in ABR | 11 |
Average Target Price | $578.67 |
LT Growth Rate | 11.10% |
Industry | Medical - Instruments |
Industry Rank by ABR | 145 of 252 |
Current Quarter EPS Est: | 2.87 |